Sanderson Simon, Salanti Georgia, Higgins Julian
Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.
Am J Epidemiol. 2007 Oct 1;166(7):741-51. doi: 10.1093/aje/kwm167. Epub 2007 Aug 4.
Bladder cancer is an increasingly important international public health problem, with over 330,000 new cases being diagnosed each year worldwide. In a systematic review and evidence synthesis, the authors investigated the joint effects of the N-acetyltransferase genes NAT1 and NAT2 and cigarette smoking on bladder carcinogenesis. Studies were identified through an exhaustive search of multiple electronic databases and reference lists and through direct contact with study authors and experts. Random-effects meta-analysis was used within a Bayesian framework to investigate individual effects of NAT1 and NAT2 acetylation status on bladder cancer risk, while a novel approach was used to investigate joint effects of these two genes with cigarette smoking. An increased risk of bladder cancer was found in NAT2 slow acetylators (odds ratio = 1.46, 95% credible interval (CI): 1.26, 1.68) but not in NAT1 fast acetylators (odds ratio = 1.01, 95% CI: 0.86, 1.22). The joint effects in the highest risk category (NAT2 slow acetylator, NAT1 fast acetylator, and current or ever cigarette smoking) as compared with the reference category (NAT2 fast acetylator, NAT1 slow acetylator, and never smoking) were associated with an odds ratio of 2.73 (95% CI: 1.70, 4.31). The importance of considering joint effects between genetic and environmental factors in the etiology of common complex diseases is underlined.
膀胱癌是一个日益重要的国际公共卫生问题,全球每年有超过33万新病例被诊断出来。在一项系统评价和证据综合分析中,作者研究了N - 乙酰转移酶基因NAT1和NAT2以及吸烟对膀胱癌发生的联合作用。通过详尽搜索多个电子数据库和参考文献列表,并通过直接联系研究作者和专家来确定研究。在贝叶斯框架内使用随机效应荟萃分析来研究NAT1和NAT2乙酰化状态对膀胱癌风险的个体影响,同时采用一种新方法来研究这两个基因与吸烟的联合作用。发现NAT2慢乙酰化者患膀胱癌的风险增加(优势比 = 1.46,95%可信区间(CI):1.26, 1.68),但NAT1快乙酰化者未增加(优势比 = 1.01,95%CI:0.86, 1.22)。与参照组(NAT2快乙酰化者、NAT1慢乙酰化者和从不吸烟者)相比,最高风险组(NAT2慢乙酰化者、NAT1快乙酰化者和当前或曾经吸烟者)的联合作用的优势比为2.73(95%CI:1.70, 4.31)。强调了在常见复杂疾病病因中考虑遗传和环境因素联合作用的重要性。